REBOUND DYNAMICS FOLLOWING IMMUNOTHERAPY WITH AN HIV VACCINE, TLR9 AGONIST, AND bNAbs (CROI 2023) - Feb 13, 2023 - Abstract #435; Pres time: Feb 21, 2023; 02:30 PM - 04:00 PM; Location: Exibit Hall 2; " We performed a single-arm proof-of-concept study to evaluate the efficacy of a combination approach involving (1) Gag conserved element (CE)-targeted DNA+IL-12 prime/MVA boost vaccination, followed by (2) a combination of two broadly neutralizing antibodies (bNAbs; 10-1074, VRC07-523LS) and a TLR-9 agonist (lefitolimod) and then (3) two bNAbs given at the time of treatment interruption. The majority of individuals who received combination immunotherapy exhibited evidence of virologic control post-ART. Treatment-mediated virologic and immunologic factors may have contributed to this outcome."
Late-breaking abstract • Human Immunodeficiency Virus • Immunology • Infectious Disease • CD4 • CD8 • IFNG • IL12A
|
|
Michael J.Peluso; Amelia Deitchman; Gesham Magombedze; Meghann Williams; Nitasha Kumar; James Mullins; Barbara K.Felber; George Pavlakis; Rowena Johnston; Jackie Reeves; Lucio Gama; Michel C.Nussenzweig; Timothy Henrich; Rachel L.Rutishauser; Steven G.Deeks
|